Evidence mapPaperPMID 41779793Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2026

Med14 phosphorylation shapes genomic response to GLP-1 agonists.

Sam Van de Velde, Jungting Yu, K Garrett Evensen, Edmund Pakhlevanyan, April E Williams, Reuben J Shaw, Marc Montminy

Abstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Med14 phosphorylation shapes genomic response to GLP-1 agonists.Proceedings of the National Academy of Sciences of the United States of America · 2026
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors.

Sam Van de VeldePeptide Biology Laboratories, The Salk Institute for Biological Studies, La Jolla, CA 92037.
Jungting YuRazavi Newman Integrative Genomics and Bioinformatics Core, The Salk Institute for Biological Studies, La Jolla, CA 92037.
K Garrett EvensenRazavi Newman Integrative Genomics and Bioinformatics Core, The Salk Institute for Biological Studies, La Jolla, CA 92037.
Edmund PakhlevanyanPeptide Biology Laboratories, The Salk Institute for Biological Studies, La Jolla, CA 92037.
April E WilliamsRazavi Newman Integrative Genomics and Bioinformatics Core, The Salk Institute for Biological Studies, La Jolla, CA 92037.
Reuben J ShawMolecular and Cell Biology Laboratory, The Salk Institute for Biological Studies, La Jolla, CA 92037.ORCID 0000-0002-1555-8977
Marc MontminyPeptide Biology Laboratories, The Salk Institute for Biological Studies, La Jolla, CA 92037.ORCID 0000-0001-8118-6174

Funding

Decoding And Targeting The LKB1-AMPK Signaling Pathway In CancerR35CA220538 · NCI · SALK INSTITUTE FOR BIOLOGICAL STUDIES · PI Reuben Shaw · 2017 to 2026
$11.3M
HHS | NIH (NIH) 5R01 DK083834NCI NIH HHS R35 CA220538
6 · The paper itself

Abstract

Binding of GLP-1 to its receptor in pancreatic beta cells triggers activation of the cAMP pathway and phosphorylation of CREB, leading to induction of cellular target genes containing CREB binding sites. By contrast with their acute effects on beta cell gene expression, chronic exposure of beta cells to stable GLP-1 analogs like Exendin-4 stimulates sustained expression of beta cell-specific genes, leading to increases in beta cell viability and insulin secretion. In a proteomic screen for transcriptional coregulators that contribute to the transcriptional effects of GLP-1, we identified Med14, the scaffolding subunit of the conserved 30 subunit Mediator complex. Exposure to Exendin-4 and other GLP-1 receptor agonists stimulates sustained phosphorylation of Med14 at Ser983, which corresponds to a conserved PKA recognition site. Mutation of Med14 at Ser983 blocked Exendin-4 effects on cellular gene expression by interfering with CREB-mediated activation of beta cell-specific enhancers. Med14 mutation results in higher alpha-to-beta cell ratios and blunted gene regulation in response to Exendin-4 in Ser983-mutant primary mouse islets. Our work reveals how phosphorylation of a general transcription factor in response to GLP-1 analogs triggers a broad genomic response with salutary effects on beta cell function.

Indexed as

Glucagon-Like Peptide 1Glucagon-Like Peptide-1 Receptor AgonistsMediator ComplexAnimalsCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinExenatideGene Expression RegulationGlucagon-Like Peptide-1 ReceptorHumansInsulinInsulin-Secreting CellsMicePeptidesPhosphorylationVenomsCyclic AMP-Dependent Protein KinasesCyclic AMP Response Element-Binding ProteinExenatideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsInsulinMediator ComplexPeptidesVenomsbeta cellsdiabetesGLP-1PKAtranscription

Identifiers

PMID41779793
PMCPMC12974444

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.